Moclobemide in patients with dementia and depression.
Moclobemide, the first reversible inhibitor of MAOA (so-called RIMA) to become widely available for clinical use, is an effective and well-tolerated antidepressant. Preclinical experiments, as well as studies in human volunteers and patients, provide evidence for the cognition enhancing effects of moclobemide. This cognition improvement, taken together with moclobemide's absence of anticholinergic effects, lack of sedation, and similarity in pharmacokinetics in young and elderly individuals, makes this drug especially appropriate for use in treatment of the elderly depressed patient.
Amrein
R
R
F. Hoffmann-La Roche, Ltd., Basel, Switzerland.
Martin
J R
JR
Cameron
A M
AM
D000818:Animals; D001549:Benzamides / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000150:complications / Q000188:drug therapy; D003704:Dementia / Q000188:drug therapy*; D003863:Depression / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*
D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D020912:Moclobemide